The timeline to wrap up the initial review phase for a potential new child and youth advocacy centre is the fall of 2027.
TG Therapeutics, Inc. (NASDAQ: TGTX), today announced the presentation of data highlighting BRIUMVI ®  (ublituximab-xiiy), to be presented at the Americas Committee for Treatment and Research in ...